THROMBIN INHIBITOR MARKET ANALYSIS

Thrombin Inhibitor Market, By Type (Direct Thrombin Inhibitors and Indirect Thrombin Inhibitors), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation (AF), and Others (stroke prevention, acute coronary syndrome, etc.)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments

New product launches

In August 2023, Fresenius Kabi Canada Ltd., a pharmaceutical company, launched anticoagulant sodium citrate 4% solution, USP, 250ml in Canada
In December 2020, Nato Pharma, a pharmaceutical company based in India, launched the Rivaroxaban molecule under the brand name RPIGAT, an anticogulant

Acquisition and partnerships

In July 2020, Alexion Pharmaceuticals, Inc., a pharmaceutical company, announced the completion of its acquisition of Portola Pharmaceuticals, Inc. The acquisition adds Factor Xa inhibitor reversal agent Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in Europe, to Alexion’s commercial portfolio.

Thrombin Inhibitor Market Report Snapshots